Puma Biotechnology, Inc. (PBYI)
| Market Cap | 380.05M +154.6% |
| Revenue (ttm) | 228.37M -0.9% |
| Net Income | 31.11M +2.8% |
| EPS | 0.61 -1.6% |
| Shares Out | 50.88M |
| PE Ratio | 12.25 |
| Forward PE | 29.88 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 264,398 |
| Open | 7.41 |
| Previous Close | 7.24 |
| Day's Range | 7.23 - 7.57 |
| 52-Week Range | 2.75 - 7.90 |
| Beta | 1.18 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 7, 2026 |
About PBYI
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breas... [Read more]
Financial Performance
In 2025, Puma Biotechnology's revenue was $228.37 million, a decrease of -0.91% compared to the previous year's $230.47 million. Earnings were $31.11 million, an increase of 2.75%.
Financial StatementsNews
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 1, 2026, the Compensation Committee of Puma's Board of Directors approved th...
Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology issued its 4Q-2025 earnings release on Feb. 26 and followed with a conference call to review results.
Puma Biotechnology to Present at TD Cowen's 46th Annual Health Care Conference
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology CEO & President Alan Auerbach will provide a corporate overview at the TD Cowen Health Care Conference on March 2 at 2:30 pm ET.
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its fourth quarter and full year 2025 results, followed be a conference call, after the close on Feb. 26, 2026.
Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology was added to the Nasdaq Biotechnology Index effective after the close of trading on Dec. 19, 2025.
Puma Biotechnology Reports Third Quarter 2025 Financial Results
LOS ANGELES--(BUSINESS WIRE)--On 11/6/26, Puma Biotechnology issued its financials for Q3-2025 and hosted a conference to discuss operating results.
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue financials and host a conference call on Nov. 6, 2025 to discuss its results for the third quarter of 2025.
Puma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment Conference
LOS ANGELES--(BUSINESS WIRE)--On 9/8/25, Puma Biotechnology CEO and President Alan Auerbach will present a company overview at the H.C. Wainwright Global Investment Conference.
Puma Biotechnology Reports Second Quarter Financial Results
LOS ANGELES--(BUSINESS WIRE)--On 8/7/2025, Puma Biotechnology issued 2Q-2025 earnings results and followed with a conference call to discuss quarterly and year-to-date results.
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results
LOS ANGELES--(BUSINESS WIRE)--On August 7, 2025, Puma Biotechnology will host a conference call/webcast to review its financial results for the second quarter of 2025.
Puma Biotechnology Reports First Quarter Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology release its 1Q'25 earnings results on May 8 after markets closed and followed with a conference call to discuss operating results.
Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients
ATHENS, Greece and LOS ANGELES, April 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies in the EMEA region, today an...
Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced Phase I data of trastuzumab deruxtecan plus neratinib in solid tumors with HER2 alterations was presented at AACR 2025.
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its 1Q-2025 results after market close on May 8, 2025, and follow with a conference call at 1:30 pm PT/4:30 pm ET.
Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will present clinical data on its drug neratinib in a poster presentation on April 28 at the 2025 AACR Annual Meeting.
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will prov...
Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its 4Q and FY-2024 earnings results after the close on Feb. 27 and follow with a conference call to discuss results.
Puma Biotechnology to Present at TD Cowen's 45th Annual Health Care Conference
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will prov...
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its 4Q and full year 2024 results on Feb. 27 and follow with a conference call at 1:30 p.m. PT/4:30 p.m. ET.
Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation
LOS ANGELES--(BUSINESS WIRE)--NCCN Guidelines for Cervical Cancer now include Puma's neratinib monotherapy for 2nd line or later use in patients with HER2-mutated tumors, Cat. 2A.
Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology has initiated a clinical trial of alisertib with endocrine therapy in patients with HR+ HER2-negative metastatic breast cancer.
Puma Biotechnology Reports Third Quarter 2024 Financial Results
LOS ANGELES--(BUSINESS WIRE)--On Nov. 7, Puma Biotechnology issued its earnings results for 3Q-2024 and hosted a conference call to discuss the details.
Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO and President of Puma Biotechnology, will present a company overview on Sept. 9 at H.C. Wainwright's 26th Annual Global Inv. Conf.
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results
LOS ANGELES--(BUSINESS WIRE)--On Aug. 1, Puma Biotechnology will issue its earnings results for the 2024 second quarter and follow with a conference call to discuss the results.
Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology Announced Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer at the 2024 ASCO Annual Meeting.